Matisse Pharmaceuticals B.V., a biotechnology company, develops pharmaceutical therapeutics for the treatment of sepsis..
It is developing M6229, which is in the pre-clinical phase for the treatment of severe sepsis and septic shock. The company also focuses on the research and development of therapies that neutralize cytotoxic components of the inflammatory system